Stock Analiz

Pro Dex Inc. PDEX

Medical/Dental Instruments · data as of November 13, 2026

$65.66Market cap $210M
Open the interactive analysis →

Pro Dex Inc. (PDEX) is a healthcare company listed in the US with a market value of about $210M. In the twelve months to September 30, 2026 it had revenue of $80M and net income of $12M, a net margin of 15.1%.

Its overall Stock Analiz score is 4.0 out of 5 (excellent). The strongest part is track record (5/5); the weakest is future growth (3/5).

Key numbers: a P/E of 18.1, a price to free cash flow of 19.7, 5-year revenue growth of 15% a year, a 5-year average ROIC of 13%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 26% below the current price.

About Pro Dex

Pro Dex is listed in the US and classified in medical/dental instruments. Revenue went from $38M in 2021 to $78M in 2026, growth of about 15.3% a year. It was profitable in 6 of the last 6 years in our data. Its share count fell by 9% over three years (buybacks). It spends 4% of revenue on research and development.

Score: 4.0 / 5

Value4/5
Future growth3/5
Track record5/5
Financial health5/5
Shareholder returns3/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 5-year EPS growth above 10% a year

Checks not passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • Pays a dividend
  • Dividend 3 years in a row

Valuation

P/E (TTM)18.1
Forward P/E20.4
P/FCF19.7
P/S2.6
P/B4.3
EV/EBITDA14.5
PEG0.85
Dividend yield0.00%
FCF yield5.1%
Shareholder yield1.6%
Intrinsic value vs. price−26%

Growth and quality

Revenue growth (1 yr)16.4%
Revenue growth (5 yrs, per year)15.3%
EPS growth (5 yrs, per year)21.3%
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)12.3%
ROIC (5-yr avg.)12.5%
Profitable years (of last 10)6
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202620252024202320222021
Revenue$80M$78M$67M$54M$46M$42M$38M
Net income$12M$14M$9M$2M$7M$5M$6M
Free cash flow$11M$7M-$3M——-$2M-$4M
EPS (diluted)$3.63$4.12$2.67$0.60$1.95$1.21$1.57
Net margin15.1%17.6%13.5%4.0%15.3%10.9%16.2%
ROIC—15.0%15.1%13.2%9.4%9.9%10.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $74.00, 13% above the current price; targets range from $74.00 to $74.00; the consensus rating is “none”; expected EPS is $3.09 for the fiscal year ending June 30, 2027.

Frequently asked questions

What is Pro Dex’s P/E ratio?

About 18.1, based on the last twelve months of diluted earnings per share (forward P/E about 20.4).

Is Pro Dex stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 26% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Pro Dex pay a dividend?

Not currently.

Is Pro Dex a good stock to buy?

We do not give buy or sell advice. Pro Dex scores 4.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.